Huapont Life Sciences Co.,Ltd. (SHE:002004)

Huapont Life Sciences Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Jan 1, 2021
Operating Revenue	11,539	11,508	11,409	13,021	12,290	10,732
Other Revenue	148.74	156.83	186.02	211.45	141.06	143.9
Revenue	11,688	11,665	11,595	13,232	12,431	10,876
Revenue Growth (YoY)	0.34%	0.60%	-12.38%	6.44%	14.29%	7.78%
Cost of Revenue	7,859	7,827	7,208	7,971	7,759	6,469
Gross Profit	3,829	3,838	4,387	5,261	4,672	4,407
Selling, General & Admin	2,228	2,259	2,550	2,904	2,753	2,579
Research & Development	382.56	375.32	419.14	385.24	329.47	324.35
Other Operating Expenses	138.24	114.96	103.47	89.41	80.78	61.02
Operating Expenses	2,783	2,770	3,080	3,386	3,188	2,929
Operating Income	1,046	1,068	1,307	1,875	1,484	1,478
Interest Expense	-325.65	-349.97	-343.7	-434.01	-461.68	-561.07
Interest & Investment Income	107.57	69.66	92.75	529.44	380.87	323
Currency Exchange Gain (Loss)	40.38	29.81	46.5	153.25	-31.74	-76.11
Other Non Operating Income (Expenses)	-24.56	-32.98	-43.03	-42.16	-55.59	-87.77
EBT Excluding Unusual Items	843.31	784.79	1,059	2,082	1,316	1,076
Impairment of Goodwill	-707.56	-707.56	-208.16	-491.85	-29.36	-
Gain (Loss) on Sale of Investments	-179.42	-194.06	1.2	-4.84	8.52	10.26
Gain (Loss) on Sale of Assets	11.94	3.75	28.11	-21.26	-22.43	2.2
Asset Writedown	-110.46	-108.59	-88.96	-31.51	-93.3	-24.15
Other Unusual Items	118.41	61.16	101.04	90.16	101.87	100.44
Pretax Income	-23.78	-160.51	892.39	1,623	1,281	1,165
Income Tax Expense	193.15	182.09	215.46	495.49	361.04	270.08
Earnings From Continuing Operations	-216.93	-342.59	676.93	1,127	920.2	895.01
Minority Interest in Earnings	-7.13	43.6	-374.81	-693.72	-252.4	-243.27
Net Income	-224.06	-298.99	302.12	433.48	667.81	651.73
Net Income to Common	-224.06	-298.99	302.12	433.48	667.81	651.73
Net Income Growth	-	-	-30.30%	-35.09%	2.47%	5.08%
Shares Outstanding (Basic)	1,973	1,975	1,980	1,980	1,980	1,975
Shares Outstanding (Diluted)	1,973	1,975	1,980	1,980	1,980	1,975
Shares Change (YoY)	-0.27%	-0.25%	-0.02%	0.02%	0.25%	-1.29%
EPS (Basic)	-0.11	-0.15	0.15	0.22	0.34	0.33
EPS (Diluted)	-0.11	-0.15	0.15	0.22	0.34	0.33
EPS Growth	-	-	-30.29%	-35.10%	2.21%	6.45%
Free Cash Flow	1,076	669.02	305.35	1,277	13.19	1,142
Free Cash Flow Per Share	0.55	0.34	0.15	0.65	0.01	0.58
Dividend Per Share	0.200	-	0.220	0.220	0.220	0.220
Dividend Growth	-9.09%	-	-	-	-	-
Gross Margin	32.76%	32.90%	37.83%	39.76%	37.58%	40.52%
Operating Margin	8.95%	9.16%	11.27%	14.17%	11.94%	13.59%
Profit Margin	-1.92%	-2.56%	2.61%	3.28%	5.37%	5.99%
Free Cash Flow Margin	9.20%	5.73%	2.63%	9.65%	0.11%	10.50%
EBITDA	2,018	1,995	2,165	2,647	2,200	2,175
EBITDA Margin	17.27%	17.10%	18.67%	20.00%	17.70%	19.99%
D&A For EBITDA	972.52	926.8	858.19	771.15	716.37	696.31
EBIT	1,046	1,068	1,307	1,875	1,484	1,478
EBIT Margin	8.95%	9.16%	11.27%	14.17%	11.94%	13.59%
Effective Tax Rate	-	-	24.14%	30.54%	28.18%	23.18%
Revenue as Reported	11,688	11,665	11,595	13,232	12,431	-
Advertising Expenses	-	410.08	610.81	758.7	887.58	979.61

Source: S&P Global Market Intelligence. Standard template. Financial Sources.